Tanja Kuhbacher
Hamburg, HH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.
Journal: Inflammatory bowel diseases
Published: June 05, 2025
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program.
Journal: Inflammatory bowel diseases
Published: July 01, 2024
Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: June 02, 2023
Submucosal Injection of the RNA Oligonucleotide GUT-1 in Active Ulcerative Colitis Patients: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Induction Trial.
Journal: Journal of Crohn's & colitis
Published: May 19, 2023
Safety and tolerability of spesolimab in patients with ulcerative colitis.
Journal: Expert opinion on drug safety
Published: July 21, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Journal: Lancet (London, England)
Published: November 03, 2021
Position paper on endoscopic reporting in IBD
Journal: Zeitschrift fur Gastroenterologie
Published: July 20, 2021
Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease.
Journal: Gastroenterology
Published: August 27, 2020
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
Journal: Gastroenterology
Published: July 01, 2019
Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.
Journal: Alimentary pharmacology & therapeutics
Published: July 05, 2017
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Journal: Lancet (London, England)
Published: November 07, 2016
Last Updated: 09/26/2026